- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 10 - Paying for Combination Therapies
Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.
Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.
If there are promising results for combination therapies, the payers will have to figure out the best population for the therapy and how it will be paid for, he said.
“I think there is a common misconception that when payers make coverage policy decisions, and I can speak only about oncology because I do not know about anything else, that they look at the price tag first and the evidence second,” he said. “That is really not how it works. So, I think the evidence is looked at first and then you start thinking about ‘how do we manage the cost?’”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More
